EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women



Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women



Journal of Clinical Endocrinology and Metabolism 78(6): 1312-1319



Modifications were made to a commercially available human (h) GH chemiluminescence assay (Nichols Luma Tag hGH assay), which improved its sensitivity to 0.002 micrograms/L. The results of this assay had a high correlation with those of the Nichols hGH immunoradiometric assay (IRMA; r = 0.91; P < 0.001). The addition of recombinant hGH-binding protein (0.1-10 nmol/L) to standards and serum samples caused a dose-responsive reduction in measured GH in both the chemiluminescence assay and the IRMA; at physiological concentrations of hGH-binding protein, a 10-20% reduction was observed. Fifteen normal young adults (nine men and six women) underwent a standard 100-g oral glucose tolerance test, and plasma GH was measured from 30 min before until 5 h after glucose ingestion. GH was measurable in all samples with the chemiluminescence assay, but fell below the sensitivity of the IRMA in 59% of the samples. There was no difference between baseline or peak glucose levels in male and female subjects, but serum GH concentrations (mean +/- SD) measured by the enhanced sensitivity chemiluminescence assay were lower in male than female subjects at both baseline (0.12 +/- 0.08 vs. 2.3 +/- 2.3 micrograms/L; P < 0.01) and the postglucose GH nadir (0.029 +/- 0.014 vs. 0.25 +/- 0.23 micrograms/L; P < 0.01). The high correlation between baseline and nadir GH (r = 0.82; P < 0.001) and the equivalent fractional decline in mean GH levels in men and women after glucose administration (67 +/- 17% vs. 84 +/- 8%; P = 0.06) suggest that the lower GH levels in men after glucose treatment are due to lower baseline values and not to a greater suppressive effect of glucose.

(PDF same-day service: $19.90)

Accession: 045967251

Download citation: RISBibTeXText

PMID: 8200931

DOI: 10.1210/jcem.78.6.8200931



Related references

Postglucose growth hormone nadir and insulin-like growth factor-1 in naïve-active acromegalic patients: do these parameters always correlate?. Arquivos Brasileiros de Endocrinologia E Metabologia 55(7): 494-497, 2012

Enhanced sensitivity of a two-site acridinium ester based immunochemiluminometric assay for rat growth hormone-releasing hormone using simple modifications in assay procedure. Journal Of Immunological Methods. 1-2: 187-189, 1996

High sensitivity two-site immunoradiometric and immunochemiluminometric assays for rat growth hormone-releasing hormone. Development of an acridinium ester based chemiluminescence assay for the avidin-coated bead system. Journal of Immunological Methods 172(2): 197-207, 1994

Growth hormone concentrations in men and women after resistance exercise are assay dependent. Medicine & Science in Sports & Exercise 31(5 SUPPL ): S229, 1999

Growth hormone concentrations in women Effects of exercise, menstrual status and assay method. FASEB Journal 13(4 PART 1): A80, March 12, 1999

Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease. Clinical Endocrinology 66(4): 538-542, 2007

Effects of human pancreatic growth hormone-releasing factor-40 on serum growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and somatomedin-C concentrations in normal women throughout the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 59(5): 1006-1010, 1984

Modified Clonidine Testing for Growth Hormone Stimulation Reveals α2-Adrenoreceptor Sub Sensitivity in Children with Idiopathic Growth Hormone Deficiency. Plos One 10(9): E0137643-E0137643, 2016

Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Advances 1(18): 1414-1422, 2018

Effects of human pancreatic growth hormone releasing factor 40 on serum growth hormone prolactin luteinizing hormone fsh and somatomedin c concentrations in normal women throughout the menstrual cycle. Journal of Clinical Endocrinology & Metabolism 59(5): 1006-1010, 1984

First results of a new chemiluminescence assay for human growth hormone in urine. European Journal of Endocrinology 130(SUPPL 2): 192, 1994

Analysis of trough serum growth hormone concentrations: comparison of an immunoradiometric assay and a sensitive ELISA for growth hormone. Clinical Endocrinology 37(2): 169-174, 1992

Measurement of human growth hormone using a chemiluminescence assay and a "glow" luminometer. Biotechniques 20(1): 48-50, 1996